EX-10.18 3 a17-1074_1ex10d18.htm EX-10.18 CHANGE IN CONTROL AND SEVERANCE AGREEMENTControl and Severance Agreement • May 5th, 2020 • Connecticut
Contract Type FiledMay 5th, 2020 JurisdictionThis Change in Control and Severance Agreement (this “Agreement”) is entered into by and between [·] (the “Executive”) and Loxo Oncology, Inc., a Delaware corporation (the “Company”), on March 6, 2017 (the “Effective Date”).
AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENTControl and Severance Agreement • January 17th, 2019 • Loxo Oncology, Inc. • Pharmaceutical preparations • Connecticut
Contract Type FiledJanuary 17th, 2019 Company Industry JurisdictionThis Amended and Restated Change in Control and Severance Agreement (this “Agreement”) is entered into by and between Jacob S. Van Naarden (the “Executive”) and Loxo Oncology, Inc., a Delaware corporation (the “Company”), on June 1, 2018 (the “Effective Date”).
AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENTControl and Severance Agreement • January 17th, 2019 • Loxo Oncology, Inc. • Pharmaceutical preparations • Connecticut
Contract Type FiledJanuary 17th, 2019 Company Industry JurisdictionThis Amended and Restated Change in Control and Severance Agreement (this “Agreement”) is entered into by and between Nisha Nanda (the “Executive”) and Loxo Oncology, Inc., a Delaware corporation (the “Company”), on June 1, 2018 (the “Effective Date”).